Lipoprotein(a), Endothelial Dysfunction and Cardiovascular Disease
Journal of Cellular and Molecular Medicine · 2026-11 · 30 (21)
DOI: 10.1111/jcmm.71426 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Cellular and Molecular Medicine, online erschienen am 06.11.2026. Verfasst von Xianghui Zhou und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. Hauptthemen laut MEDLINE: Lipoprotein(a), Cardiovascular Diseases, Endothelium, Vascular, Endothelial Cells. Die Arbeit nennt 110 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key Research and Development Program of China, National Natural Science Foundation of China, Natural Science Foundation of Hubei Province.
Abstract (Originalsprache)
Lipoprotein(a) (Lp(a)) is a particle similar to low‐density lipoprotein cholesterol and is associated with apolipoprotein (A). High Lp(a) levels are a genetic, independent risk factor for atherosclerotic cardiovascular disease (ASCVD). Endothelial cells, which form the continuous lining of the cardiovascular system, are crucial for vascular function and represent the primary target of Lp(a)‐mediated injury. Lp(a) penetrates the endothelial barrier and undergoes oxidative modification, triggering endothelial dysfunction, which is characterized by inflammation, oxidative stress and impaired nitric oxide bioavailability. These disruptions promote monocyte recruitment, foam cell formation and atherosclerosis development. Currently, various drugs that can reduce Lp(a) levels are also involved in regulating endothelial cell function, ultimately reducing the risk of ASCVD. However, the molecular mechanisms underlying Lp(a)‐mediated endothelial injury and the extent to which Lp(a) lowering improves endothelial function remain incompletely defined. Clarifying these issues may inform cardiovascular risk stratification and the clinical development of Lp(a)‐targeted therapies. This review seeks to consolidate the understanding of the link between Lp(a) levels and endothelial dysfunction, highlighting its pivotal role in cardiovascular disease progression.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
- Department of Stomatology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
- Hubei Clinical Medical Center of Cell Therapy for Neoplastic Disease, Wuhan, China.
ORCID-Profile: Xianghui Zhou, Zhao Zhang, Yu Hu
Förderung
- National Key Research and Development Program of China
- National Natural Science Foundation of China
- Natural Science Foundation of Hubei Province
Zitieren
APA
Zhou, X., Fang, X., Zhou, X., Zhang, Z., Hu, Y., & Cheng, Z. (2026). Lipoprotein(a), Endothelial Dysfunction and Cardiovascular Disease. Journal of Cellular and Molecular Medicine, 30(21). https://doi.org/10.1111/jcmm.71426
Vancouver
Zhou X, Fang X, Zhou X, Zhang Z, Hu Y, Cheng Z. Lipoprotein(a), Endothelial Dysfunction and Cardiovascular Disease. Journal of Cellular and Molecular Medicine. 2026;30(21). doi:10.1111/jcmm.71426
BibTeX
@article{Zhou2026,
author = {Zhou, Xianghui and Fang, Xiyuan and Zhou, Xin and Zhang, Zhao and Hu, Yu and Cheng, Zhipeng},
title = {Lipoprotein(a), Endothelial Dysfunction and Cardiovascular Disease},
journal = {Journal of Cellular and Molecular Medicine},
year = {2026},
volume = {30},
number = {21},
doi = {10.1111/jcmm.71426}
}
EUVIMED